NCT03827876

Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis

An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Psoriasis Treatment Center of Central New Jersey · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks

Detailed description

30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar® once daily for 4 weeks followed by QOD for 12 weeks.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Enstilar 0.005%-0.064% Topical Foam	Enstilar 0.005%-0.064% Topical Foam applied once daily for 4 weeks followed by QOD for 12 weeks for patients receiving Enbrel or Humira

Timeline

• Start date: 2019-01-16
• Primary completion: 2019-09-15
• Completion: 2019-12-15
• First posted: 2019-02-04
• Last updated: 2019-02-04

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study